These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29088896)

  • 41. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.
    Jassem J; Fein L; Karwal M; Campone M; Peck R; Poulart V; Vahdat L
    Breast; 2012 Feb; 21(1):89-94. PubMed ID: 21937232
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis.
    Caramelo O; Silva C; Caramelo F; Frutuoso C; Pinto L; Almeida-Santos T
    Hered Cancer Clin Pract; 2022 Sep; 20(1):34. PubMed ID: 36085046
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
    González-Rivera M; Lobo M; López-Tarruella S; Jerez Y; Del Monte-Millán M; Massarrah T; Ramos-Medina R; Ocaña I; Picornell A; Santillán Garzón S; Pérez-Carbornero L; García-Saenz JA; Gómez H; Moreno F; Márquez-Rodas I; Fuentes H; Martin M
    Breast Cancer Res Treat; 2016 Apr; 156(3):507-515. PubMed ID: 27083178
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
    Dandamudi RK; Aslam S; Walji N; El-Modir A; Fernando I
    Anticancer Res; 2015 Sep; 35(9):4841-7. PubMed ID: 26254376
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Optimal Systemic Treatment for Early Triple-Negative Breast Cancer.
    Furlanetto J; Loibl S
    Breast Care (Basel); 2020 Jun; 15(3):217-226. PubMed ID: 32774215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women.
    Pentheroudakis G; Fountzilas G; Bafaloukos D; Koutsoukou V; Pectasides D; Skarlos D; Samantas E; Kalofonos HP; Gogas H; Pavlidis N
    Breast Cancer Res Treat; 2006 Jun; 97(3):237-44. PubMed ID: 16322882
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer.
    Abreu de Oliveira WA; Moens S; El Laithy Y; van der Veer BK; Athanasouli P; Cortesi EE; Baietti MF; Koh KP; Ventura JJ; Amant F; Annibali D; Lluis F
    Front Oncol; 2021; 11():705384. PubMed ID: 34367990
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of platinum-based chemotherapy in triple-negative breast cancer patients with metastases confined to the lungs: a single-institute experience.
    Hong R; Ma F; Xu B; Li Q; Zhang P; Yuan P; Wang J; Fan Y; Cai R
    Anticancer Drugs; 2014 Oct; 25(9):1089-94. PubMed ID: 25153786
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
    Lee A; Go SI; Lee WS; Lee US; Kim MJ; Kang MH; Lee GW; Kim HG; Kang JH; Jeon KN; Cho JM; Lee JH
    Tumori; 2015 Mar; 101(1):e9-e12. PubMed ID: 25702650
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer.
    Locatelli MA; Curigliano G; Eniu A
    Breast Care (Basel); 2017 Jul; 12(3):152-158. PubMed ID: 28785182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of delayed adjuvant chemotherapy on relapse of triple-negative breast cancer.
    Li S; Ma D; Shi HH; Yu KD; Zhang Q
    J Thorac Dis; 2018 May; 10(5):2837-2841. PubMed ID: 29997947
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM).
    Dieci MV; Del Mastro L; Cinquini M; Montemurro F; Biganzoli L; Cortesi L; Zambelli A; Criscitiello C; Levaggi A; Conte B; Calabrese M; Fiorentino A; Marchiò C; Tinterri C; Fittipaldo VA; Pappagallo G; Gori S
    Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31398896
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown
    Su YW; Hung CY; Lam HB; Chang YC; Yang PS
    Clin Med Insights Oncol; 2018; 12():1179554918794672. PubMed ID: 30150877
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach.
    Kim H; Kim HJ; Kim H; Kim HR; Jo H; Hong J; Kim R; Kim JY; Ahn JS; Im YH; Lee SK; Kim H; Shin SY; Park YH
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830990
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemotherapy Decision-Making and Survival Outcomes in Older Women With Early Triple-Negative Breast Cancer: Evidence From Real-World Practice.
    Xiu M; Zhang P; Li Q; Yuan P; Wang J; Luo Y; Ma F; Cai R; Fan Y; Li Q; Xu B
    Front Oncol; 2022; 12():867583. PubMed ID: 35574419
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metronomic chemotherapy for non-metastatic triple negative breast cancer: Selection is the key.
    Rabanal C; Ruiz R; Neciosup S; Gomez H
    World J Clin Oncol; 2017 Dec; 8(6):437-446. PubMed ID: 29291168
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression.
    Khalaf D; Hilton JF; Clemons M; Azoulay L; Yin H; Vandermeer L; Dent S; Hopkins S; Bouganim N
    Oncol Lett; 2014 Mar; 7(3):866-870. PubMed ID: 24527094
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HORMAD1 overexpression predicts response to anthracycline-cyclophosphamide and survival in triple-negative breast cancers.
    El-Botty R; Vacher S; Mainguené J; Briaux A; Ibadioune S; Dahmani A; Montaudon E; Nemati F; Huguet L; Sourd L; Morriset L; Château-Joubert S; Dubois T; Maire V; Lidereau R; Rapinat A; Gentien D; Coussy F; Bièche I; Marangoni E
    Mol Oncol; 2023 Oct; 17(10):2017-2028. PubMed ID: 36852691
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer.
    McAndrew N; DeMichele A
    J Target Ther Cancer; 2018 Feb; 7(1):52-69. PubMed ID: 29577076
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chemotherapy regimen choice and patient outcomes in early-stage triple-negative breast cancer: a retrospective analysis.
    Ghafouri SN; Nayeri RW; McAndrew NP; Hurvitz SA
    Ther Adv Med Oncol; 2022; 14():17588359221085556. PubMed ID: 35401793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.